Osaka, Japan

Atsushi Ishikado

This inventor holds 1 USPTO granted patent and 1 published patent application and 2 EPO patents. Top assignee: Sunstar Inc.. Active years: 2020.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Atsushi Ishikado

Introduction

Atsushi Ishikado is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of biochemistry, particularly in the development of peptides with therapeutic applications. His work has implications for health and medicine, showcasing the importance of innovation in scientific research.

Latest Patents

Ishikado holds a patent for "Tripeptides having angiotensin converting enzyme inhibitory activity and uses thereof." This patent describes a novel peptide that exhibits ACE inhibitory activity, specifically a tripeptide consisting of Leu-Arg-Ala. This innovation has potential applications in treating conditions related to hypertension and cardiovascular health.

Career Highlights

Ishikado is associated with Sunstar Inc., a company known for its commitment to health and wellness products. His role at Sunstar has allowed him to focus on research and development, contributing to advancements in peptide technology. His work exemplifies the intersection of scientific research and practical applications in the health industry.

Collaborations

Ishikado has collaborated with talented colleagues such as Naohisa Shobako and Etsuko Kobayashi. These partnerships have fostered a collaborative environment that enhances innovation and drives research forward.

Conclusion

Atsushi Ishikado's contributions to peptide research and his innovative patent highlight the vital role of inventors in advancing health science. His work continues to inspire future developments in the field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…